Curry and cauliflower could halt prostate cancer

January 15, 2006

Rutgers researchers have found that the curry spice turmeric holds real potential for the treatment and prevention of prostate cancer, particularly when combined with certain vegetables.

The scientists tested turmeric, also known as curcumin, along with phenethyl isothiocyanate (PEITC), a naturally occurring substance particularly abundant in a group of vegetables that includes watercress, cabbage, winter cress, broccoli, Brussels sprouts, kale, cauliflower, kohlrabi and turnips. "The bottom line is that PEITC and curcumin, alone or in combination, demonstrate significant cancer-preventive qualities in laboratory mice, and the combination of PEITC and curcumin could be effective in treating established prostate cancers," said Ah-Ng Tony Kong, a professor of pharmaceutics at Rutgers, The State University of New Jersey.

The discovery was announced in the Jan. 15 issue of the journal Cancer Research by Kong and his colleagues at Rutgers' Ernest Mario School of Pharmacy.

Prostate cancer is the second leading cause of cancer death in men in the United States, with a half-million new cases appearing each year. The incidence and mortality of prostate cancer have not decreased in past decades despite tremendous efforts and resources devoted to treatment. This is because advanced prostate cancer cells are barely responsive even to high concentrations of chemotherapeutic agents or radiotherapy.

The authors noted that in contrast to the high incidence of prostate cancer in the United States, the incidence of this disease is very low in India. This has been attributed to the dietary consumption of large amounts of plant-based foods rich in phytochemicals - nonnutritive plant chemicals that have protective or disease-preventive properties.

Consequently, scientists have been investigating intervention options based on compounds found in edible and medicinal plants. They have had some success, and a majority of patients with prostate cancer are now combining the conventional therapies with these compounds as alternative, supplementary or complementary medications.

For Kong's study, researchers used mice bred so that their immune systems would not reject foreign biological material and injected the mice with cells from human prostate cancer cell lines to grow tumors against which the compounds could be tested.

"Despite convincing data from laboratory cell cultures, we knew little about how PEITC and curcumin would perform in live animals, especially on prostate cancer," Kong said. "So we undertook this study to evaluate how effective PEITC and curcumin might be - individually and in combination - to prevent and possibly treat prostate cancer."

The researchers injected the mice with curcumin or PEITC, alone or in combination, three times a week for four weeks, beginning a day before the introduction of the prostate cancer cells. They found the injections significantly retarded the growth of cancerous tumors. Using PEITC and curcumin in tandem produced even stronger effects.

The group went on to evaluate the therapeutic potential of curcumin and PEITC in mice with well-established tumors, and the results showed that PEITC or curcumin alone had little effect, whereas the combination of curcumin and PEITC significantly reduced tumor growth.
-end-
The paper, "Combined Inhibitory Effects of Curcumin and Phenethyl Isothiocyanate on the Growth of Human PC-3 Prostate Xenografts in Immunodeficient Mice," is available at cancerres.aacrjournals.org.

The authors are Tin Oo Khor, Young-Sam Keum, Wen Lin, Jung-Hwan Kim, Rong Hu, Guoxiang Shen, Changjiang Xu, Avanthika Gopalakrishnan, Bandaru Reddy, Xi Zheng, Allan H. Conney and Ah-Ng Tony Kong, all from Rutgers.

Rutgers University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.